3D Gamma Analysis Research Articles

Real-time high spatial resolution dose verification in stereotactic motion adaptive arc radiotherapy.

PurposeRadiation treatments delivered with real‐time multileaf collimator (MLC) tracking currently lack fast pretreatment or real‐time quality assurance. The purpose of this study is to test a 2D silicon detector, MagicPlate‐512 (MP512), in a complex clinical environment involving real‐time reconfiguration of the MLC leaves during target tracking.Methods MP512 was placed in the center of a solid water phantom and mounted on a motion platform used to simulate three different patient motions. Electromagnetic target tracking was implemented using the Calypso system (Varian Medical Systems, Palo Alto, CA, USA) and an MLC tracking software. A two‐arc VMAT plan was delivered and 2D dose distributions were reconstructed by MP512, EBT3 film, and the Eclipse treatment planning system (TPS). Dose maps were compared using gamma analysis with 2%/2 mm and 3%/3 mm acceptance criteria. Dose profiles were generated in sup‐inf and lateral directions to show the agreement of MP512 to EBT3 and to highlight the efficacy of the MLC tracking system in mitigating the effect of the simulated patient motion.ResultsUsing a 3%/3 mm acceptance criterion for 2D gamma analysis, MP512 to EBT3 film agreement was 99% and MP512 to TPS agreement was 100%. For a 2%/2 mm criterion, the agreement was 95% and 98%, respectively. Full width at half maximum and 80%/20% penumbral width of the MP512 and EBT3 dose profiles agreed within 1 mm and 0.5 mm, respectively. Patient motion increased the measured dose profile penumbral width by nearly 2 mm (with respect to the no‐motion case); however, the MLC tracking strategy was able to mitigate 80% of this effect.Conclusions MP512 is capable of high spatial resolution 2D dose reconstruction during adaptive MLC tracking, including arc deliveries. It shows potential as an effective tool for 2D small field dosimetry and pretreatment quality assurance for MLC tracking modalities. These results provide confidence that detector‐based pretreatment dosimetry is clinically feasible despite fast real‐time MLC reconfigurations.

A photon source model based on particle transport in a parameterized accelerator structure for Monte Carlo dose calculations.

An accurate source model of a medical linear accelerator is essential for Monte Carlo (MC) dose calculations. This study aims to propose an analytical photon source model based on particle transport in parameterized accelerator structures, focusing on a more realistic determination of linac photon spectra compared to existing approaches. We designed the primary and secondary photon sources based on the photons attenuated and scattered by a parameterized flattening filter. The primary photons were derived by attenuating bremsstrahlung photons based on the path length in the filter. Conversely, the secondary photons were derived from the decrement of the primary photons in the attenuation process. This design facilitates these sources to share the free parameters of the filter shape and be related to each other through the photon interaction in the filter. We introduced two other parameters of the primary photon source to describe the particle fluence in penumbral regions. All the parameters are optimized based on calculated dose curves in water using the pencil-beam-based algorithm. To verify the modeling accuracy, we compared the proposed model with the phase space data (PSD) of the Varian TrueBeam 6 and 15MV accelerators in terms of the beam characteristics and the dose distributions. The EGS5 Monte Carlo code was used to calculate the dose distributions associated with the optimized model and reference PSD in a homogeneous water phantom and a heterogeneous lung phantom. We calculated the percentage of points passing 1D and 2D gamma analysis with 1%/1mm criteria for the dose curves and lateral dose distributions, respectively. The optimized model accurately reproduced the spectral curves of the reference PSD both on- and off-axis. The depth dose and lateral dose profiles of the optimized model also showed good agreement with those of the reference PSD. The passing rates of the 1D gamma analysis with 1%/1mm criteria between the model and PSD were 100% for 4×4, 10×10, and 20×20cm2 fields at multiple depths. For the 2D dose distributions calculated in the heterogeneous lung phantom, the 2D gamma pass rate was 100% for 6 and 15MV beams. The model optimization time was less than 4min. The proposed source model optimization process accurately produces photon fluence spectra from a linac using valid physical properties, without detailed knowledge of the geometry of the linac head, and with minimal optimization time.

Efficient double-scattering proton therapy with a patient-specific bolus

PurposePassive scattering proton radiotherapy utilizes beam-specific compensators to shape the dose to the distal end of the tumor target. These compensators typically require therapists to enter the treatment room to mount between beams. This study investigates a novel approach that utilizes a single patient-specific bolus to accomplish the role of multi-field compensators to improve the efficiency of the treatment delivery. MethodsRay-tracing from the proton virtual source was used to convert the beam-specific compensators (mounted on the gantry nozzle) into an equivalent bolus thickness on the patient surface. The field bolus contours were combined to create a single bolus. A 3D acrylic bolus was milled for a head phantom. The dose distribution of the compensator plan was compared to the bolus plan using 3D Gamma analysis and film measurements. Boluses for two clinical patients were also designed. ResultsThe calculated phantom dose distribution of the original proton compensator plan was shown to be equivalent to the plan with the surface bolus. Film irradiations with the proton bolus also confirmed the dosimetric equivalence of the two techniques. The dose distribution equivalency of the bolus plans for the clinical patients were demonstrated. ConclusionsWe presented a novel approach that uses a single patient-specific bolus to replace patient compensators during passive scattering proton delivery. This approach has the potential to reduce the treatment time, the compensator manufacturing costs, the risk of potential collision between the compensator and the patient/couch, and the waste of compensator material.

Verification of Acuros XB dose algorithm using 3D printed low-density phantoms for clinical photon beams.

The transport‐based dose calculation algorithm Acuros XB (AXB) has been shown to accurately account for heterogeneities primarily through comparisons with Monte Carlo simulations. This study aims to provide additional experimental verification of AXB for clinically relevant flattened and unflattened beam energies in low density phantoms of the same material. Polystyrene slabs were created using a bench‐top 3D printer. Six slabs were printed at varying densities from 0.23 to 0.68 g/cm3, corresponding to different density humanoid tissues. The slabs were used to form different single and multilayer geometries. Dose was calculated with Eclipse™ AXB 11.0.31 for 6MV, 15MV flattened and 6FFF (flattening filter free) energies for field sizes of 2 × 2 and 5 × 5 cm2. EBT3 film was inserted into the phantoms, which were irradiated. Absolute dose profiles and 2D Gamma analyses were performed for 96 dose planes. For all single slab configurations and energies, absolute dose differences between the AXB calculation and film measurements remained <3% for both fields in the high‐dose region, however, larger disagreement was seen within the penumbra. For the multilayered phantom, percentage depth dose with AXB was within 5% of discrete film measurements. The Gamma index at 2%/2 mm averaged 98% in all combinations of fields, phantoms and photon energies. The transport‐based dose algorithm AXB is in good agreement with the experimental measurements for small field sizes using 6MV, 6FFF and 15MV beams adjacent to various low‐density heterogeneous media. This work provides preliminary experimental grounds to support the use of AXB for heterogeneous dose calculation purposes.

Refinement of MLC modeling improves commercial QA dosimetry system for SRS and SBRT patient-specific QA.

Mobius 3D (M3D) provides a volumetric dose verification of the treatment planning system's calculated dose using an independent beam model and a collapsed cone convolution superposition algorithm. However, there is a lack of investigation into M3D's accuracy and effectiveness for stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) quality assurance (QA). Here, we collaborated with the vendor to develop a revised M3D beam model for SRS/SBRT cases treated with a 6X flattening filter-free (FFF) beam and high-definition multiple leaf collimator (HDMLC) on an Edge linear accelerator. Eighty SRS/SBRT cases, planned with AAA dose algorithm and validated with Gafchromic film, were compared to M3D dose calculations using 3D gamma analysis with 2%/2 mm gamma criteria and a 10% threshold. A revised beam model was developed by refining the HD-MLC model in M3D to improve small field dose calculation accuracy and beam profile agreement. All cases were reanalyzed using the revised beam model. The impact of heterogeneity corrections for lung cases was investigated by applying lung density overrides to five cases. For the standard and revised beam models, respectively, the mean gamma passing rates were 94.6% [standard deviation (SD): 6.1%] and 98.0% [SD: 1.7%] (for the overall patient), 88.2% [SD: 17.3%] and 93.8% [SD: 6.8%] (for the brain PTV), 71.4% [SD: 18.4%] and 81.5% [SD: 14.3%] (for the lung PTV), 83.3% [SD: 16.7%] and 67.9% [SD: 23.0%] (for the spine PTV), and 78.6% [SD: 14.0%] and 86.8% [SD: 12.5%] (for the PTV of all other sites). The lung PTV mean gamma passing rates improved from 74.1% [SD: 7.5%] to 89.3% [SD: 7.2%] with the lung density overridden. The revised beam model achieved an output factor within 3% of plastic scintillator measurements for 2 × 2 cm2 MLC field size, but larger discrepancies are still seen for smaller field sizes which necessitate further improvement of the beam model. Special attention needs to be paid to small field dosimetry, MLC modeling, and inhomogeneity corrections in the beam model for SRS/SBRT QA. The improvements noted in this study, and further collaborations between clinical physicists and the vendor to refine the M3D beam model could enable M3D to become a premier SRS/SBRT QA tool.

Correlation between gamma passing rate and complexity of IMRT plan due to MLC position errors

PurposeThis study evaluates the correlation between the susceptibility of the γ passing rate of IMRT plans to the multi-leaf collimator (MLC) position errors and a quantitative plan complexity metric. MethodsTwenty patients were selected for this study. For each patient, two IMRT plans were generated using sliding window and step-&-shoot techniques, respectively. Modulation complexity score (MCS) was calculated for all IMRT plans, and symmetric MLC leaf bank errors, ranging from 0.3 mm to 1 mm, were introduced. Original and modified plans were delivered using Varian’s Clinac iX. The obtained dose distribution using ArcCHECK was then compared with the TPS calculated dose distribution of the original plans. 3D gamma analysis was performed for each verification with passing criteria of 2%/2 mm. The γ passing rate decreasing gradient were calculated to evaluate relationship between variation of γ passing rate due to MLC errors and complexity. ResultsA linear regression analysis was applied between γ gradient and complexity, and the results showed a linear correlation (R2 = 0.81 and 0.82 for open and closed MLC error types, respectively) indicating the more complex plans are more susceptible to MLC leaf bank errors. Meanwhile, correlation of re-normalized γ passing rate and complexity for all errors scenarios also presented a strong correlation (r > 0.75). ConclusionThe statistics results revealed variation relationship of dosimetry robust of plans with various complexities to MLC errors. Our results also suggested that the observed susceptibility is independent of the delivery techniques.

Experimental validation of a deforming grid 4D dose calculation for PBS proton therapy

The aim of this study was to verify the temporal accuracy of the estimated dose distribution by a 4D dose calculation (4DDC) in comparison to measurements. A single-field plan (0.6 Gy), optimised for a liver patient case (CTV volume: 403cc), was delivered to a homogeneous PMMA phantom and measured by a high resolution scintillating-CCD system at two water equivalent depths. Various motion scenarios (no motion and motions with amplitude of 10 mm and two periods: 3.7 s and 4.4 s) were simulated using a 4D Quasar phantom and logged by an optical tracking system in real-time. Three motion mitigation approaches (single delivery, 6 layered and volumetric rescanning) were applied, resulting in 10 individual measurements. 4D dose distributions were retrospectively calculated in water by taking into account the delivery log files (retrospective) containing information on the actually delivered spot positions, fluences, and time stamps. Moreover, in order to evaluate the sensitivity of the 4DDC inputs, the corresponding prospective 4DDCs were performed as a comparison, using the estimated time stamps of the spot delivery and repeated periodical motion patterns. 2D gamma analyses and dose-difference-histograms were used to quantify the agreement between measurements and calculations for all pixels with 5% of the maximum calculated dose. The results show that a mean gamma score of 99.2% with standard deviation 1.0% can be achieved for 3%/3 mm criteria and all scenarios can reach a score of more than 95%. The average area with more than 5% dose difference was 6.2%. Deviations due to input uncertainties were obvious for single scan deliveries but could be smeared out once rescanning was applied. Thus, the deforming grid 4DDC has been demonstrated to be able to predict the complex patterns of 4D dose distributions for PBS proton therapy with high dosimetric and geometric accuracy, and it can be used as a valid clinical tool for 4D treatment planning, motion mitigation selection, and eventually 4D optimisation applications if the correct temporal information is available.

Patient-specific calibration of cone-beam computed tomography data sets for radiotherapy dose calculations and treatment plan assessment.

PurposeIn this work, we propose a new method of calibrating cone beam computed tomography (CBCT) data sets for radiotherapy dose calculation and plan assessment. The motivation for this patient‐specific calibration (PSC) method is to develop an efficient, robust, and accurate CBCT calibration process that is less susceptible to deformable image registration (DIR) errors.MethodsInstead of mapping the CT numbers voxel‐by‐voxel with traditional DIR calibration methods, the PSC methods generates correlation plots between deformably registered planning CT and CBCT voxel values, for each image slice. A linear calibration curve specific to each slice is then obtained by least‐squares fitting, and applied to the CBCT slice's voxel values. This allows each CBCT slice to be corrected using DIR without altering the patient geometry through regional DIR errors.A retrospective study was performed on 15 head‐and‐neck cancer patients, each having routine CBCTs and a middle‐of‐treatment re‐planning CT (reCT). The original treatment plan was re‐calculated on the patient's reCT image set (serving as the gold standard) as well as the image sets produced by voxel‐to‐voxel DIR, density‐overriding, and the new PSC calibration methods. Dose accuracy of each calibration method was compared to the reference reCT data set using common dose‐volume metrics and 3D gamma analysis. A phantom study was also performed to assess the accuracy of the DIR and PSC CBCT calibration methods compared with planning CT.ResultsCompared with the gold standard using reCT, the average dose metric differences were ≤ 1.1% for all three methods (PSC: −0.3%; DIR: −0.7%; density‐override: −1.1%). The average gamma pass rates with thresholds 3%, 3 mm were also similar among the three techniques (PSC: 95.0%; DIR: 96.1%; density‐override: 94.4%).ConclusionsAn automated patient‐specific calibration method was developed which yielded strong dosimetric agreement with the results obtained using a re‐planning CT for head‐and‐neck patients.

A Practical Method to Optimize Quality Assurance Results of Arc Therapy Plans in Beam Modeling.

Dosimetric accuracy of a volumetric modulated arc therapy (VMAT) plan is directly related to the beam model, particularly with multileaf collimator characterization. Inappropriate dosimetric leaf gap (DLG) value can lead to a suboptimal beam model, with significant failure in patient-specific quality assurance (PSQA) of VMAT plans. This study addressed the systematic issue of beam modeling and developed a practical method to determine the optimal DLG value for a beam model. Several complex VMAT plans were selected for the quality assurance analysis using the variable DLG values. The results of three-dimensional (3D) Gamma analysis as a function of the DLG at 3%/3 mm, 2%/2 mm, and 1%/1 mm criteria were fitted by a polynomial curve. The DLG value corresponding to the maximum Gamma passing rate for each polynomial fitting function was derived, and the average was calculated to be the optimal DLG value for each model. The 3D Gamma analysis was repeated with the optimal DLG value to verify the dosimetric accuracy of each VMAT case by PSQA. Gamma passing rates are seen to vary considerably with the DLG values and different analysis criteria (3%/3 mm, 2%/2 mm, and 1%/1 mm) for each case. The optimal DLG derived for each model was 1.16 mm and 1.10 mm, much larger than the measured value (about 0.3 mm). The beam models with the optimal DLG was able to produce an average Gamma passing rate of 97.1% (range, 94.6%– 99.1%) at 3%/3 mm and 93.5% (range, 89.0%– 96.5%) at 2%/2 mm for one beam model, and 97.1% (range, 94.8%– 99.1%) at 3%/3 mm, and 93.3% (range, 88.8%– 96.7%) at 2%/2 mm for another. The overall accuracy of dose calculation for VMAT plans should be optimized with a compromise of varied modulation complexities in a beam model. We have developed a practical method to derive the optimal DLG value for each beam model based on the Gamma passing criterion. This technique should be applicable in general for all beam energies and patient cases.

43. CBCT dose calculation: accuracy assessment of four different methods

Introduction Cone Beam CT (CBCT) images aim at target volume repositioning before treatment fraction. These images may be used for dose calculation in order to dosimetrically quantify anatomical variations that occurs during treatment. The main limits are image quality, Hounsfield numbers (HU) consistency and CBCT reconstruction size. This study aims to assess accuracy of several CBCT dose calculation methods. Methods This study deals with four CBCT (XVI, Elekta) and CT image sets acquired on the same day in context of weekly dose planning of one H&N patient treated with VMAT technique. CT-CBCT sets were used to quantify CBCT dose calculation accuracy by investigating four methods: (i) use of a density to HU relation from phantom CBCT image (phantom HU-D relation), (ii) use of a density to HU relation from patient CBCT image (patient HU-D relation), (iii) density override by three classes threshold (air, soft tissues, bone) and (iv) elastic deformation (Admire, Elekta) between planning CT and CBCT image, by creating a pseudo-CT. After rigid registration, plan characteristics are projected on CBCT images (or pseudo-CT) with Pinnacle v.9.10 (Philips). Dose distribution comparison between CT-based (reference) and CBCT-based calculation was performed by a gamma analysis in 2D and 3D ( γ 2D and γ 3D, criteria: 2%/2 mm, 30% threshold). Then, dose differences were reported in terms of 95% target coverage, parotid glands mean dose (Dmean) and PRV spinal cord maximum dose (D2%). Results On average, γ 3D (percentage of points with gamma The gamma analysis showed location of discrepancy areas: near body contour, regarding shoulders and in presence of heterogeneities ( Fig. 1 ). These differences can be explained by the poor image quality and the HU inconsistency of CBCT images in some areas. The method with pseudo-CT seems to be the best to pass over these issues because densities come from planning CT. Conclusions The four evaluated methods show that dose differences can reach 5% for parotid glands and are lower than 2% for spinal cord and target volumes. The 3D gamma analysis results (2%/2 mm) are higher than 95% for three among four methods. However, additional uncertainties have to be taken into consideration in case of CBCT image delineation and/or calculation on truncated images. This preliminary study shows CBCT dose calculation feasibility to quantify impact of patient anatomical variations during treatment and trigger a new plan based on CT if necessary. The future work is real delivered dose monitoring, based on CBCT image, in perspective of dose guided adaptive radiotherapy.

Compass model-based quality assurance for stereotactic VMAT treatment plans

PurposeTo use Compass as a model-based quality assurance (QA) tool for stereotactic body radiation therapy (SBRT) and stereotactic radiation therapy (SRT) volumetric modulated arc therapy (VMAT) treatment plans calculated with Eclipse treatment planning system (TPS). Materials and methodsTwenty clinical stereotactic VMAT SBRT and SRT treatment plans were blindly selected for evaluation. Those plans included four different treatment sites: prostate, brain, lung and body. The plans were evaluated against dose-volume histogram (DVH) parameters and 2D and 3D gamma analysis. The dose calculated with Eclipse treatment planning system (TPS) was compared to Compass calculated dose (CCD) and Compass reconstructed dose (CRD). ResultsThe maximum differences in mean dose of planning target volume (PTV) were 2.7 ± 1.0% between AAA and Acuros XB calculation algorithm TPS dose, −7.6 ± 3.5% between Eclipse TPS dose and CCD dose and −5.9 ± 3.7% between Eclipse TPS dose and CRD dose for both Eclipse calculation algorithms, respectively. 2D gamma analysis was not able to identify all the cases that 3D gamma analysis specified for further verification. ConclusionsCompass is suitable for QA of SBRT and SRT treatment plans. However, the QA process should include wide set of DVH-based dose parameters and 3D gamma analysis should be the preferred method when performing clinical patient QA. The results suggest that the Compass should not be used for smaller field sizes than 3 × 3 cm2 or the beam model should be adjusted separately for both small (FS ≤ 3 cm) and large (FS > 3 cm) field sizes.

Brain MR-Only Using a Hybrid CT

The accuracy of synthetic CT images, generated for the MR-only workflow, can be challenged by tissue segmentation errors as well as improper electron density assignment for a given patient. At some point during their diagnostic workup most brain tumor patients are imaged with CT. Furthermore, many centers perform brain MR simulation using diagnostic RF coils and then apply rigid registration to align the MR images to planning CT images. We demonstrate here that the inverse approach (applying rigid registration to align diagnostic CT images to planning MR images) can be used to generate hybrid CTs suitable for the MR-only workflow in brain. Twelve brain tumor patients, immobilized in treatment masks, were imaged on a Siemens 3T using a clinical MR simulation protocol. A 3D T1 image was selected as the reference dataset. Hybrid CTs were constructed in MIM (MIM Software) as follows: 1) DICOM screeners verified 3D T1 integrity (axial slices, WFS<1mm, 3D GNL correction), 2) 3D T1 images were standardized, 3) non-contrast diagnostic CTs were upsampled and rigidly registered to 3D T1 images, 4) an external patient contour generated from the 3D T1 was filled with HU value of water, 5) voxels within the external contour were replaced by diagnostic CT voxels wherever possible. The hybrid CTs were then transferred to Monaco (Elekta) where two dosimetric comparisons were performed: 1) original VMAT plans were templated and recalculated on the hybrid CTs, and 2) VMAT plans were reoptimized on the hybrid CTs and then recalculated on the planning CTs. The Gammex 467 phantom was imaged with the brain protocol on diagnostic CT scanners to verify CTED conversion agreement with the clinical CTED file in Monaco. Dose distributions were compared using 3D gamma analysis in 3DVH (Sun Nuclear). D95PTV and OAR dose-volume constraints were also compared. All patients had non-contrast diagnostic CTs prior to MR simulation. No significant difference in CTED assignment existed from the diagnostic CT scanners. As shown in the Table, 3D dose distribution matching rates were within 1.6% and D95PTV percent differences were within 1.2%. OAR dose-volume parameters were consistent between plans calculated on planning and hybrid CTs. These results demonstrate that, by using an actual CT of the patient, hybrid CTs eliminate a majority of segmentation and density assignment uncertainties that can affect the accuracy of dose calculation. DRRs were successfully generated from the hybrid CTs and transferred to Mosaiq (Elekta) and XVI (Elekta). Standardized 3D T1 images were successfully transferred to XVI and loaded as reference images for IGRT. Hybrid CTs, suitable for the brain MR-only workflow, can be constructed from rigid registration of diagnostic CTs to planning MR images. No additional scan time or custom sequences are required.Abstract 3688Original Plan Recalculated on Hybrid CTReoptimized Plan Recalculated on Planning CT3D Match Rate; D95PTV %Diff3D Match Rate; D95PTV %Diff99.1%; 0%98.4%; -1.2% Open table in a new tab

Evaluation of a composite Gel-Alanine phantom on an end-to-end test to treat multiple brain metastases by a single isocenter VMAT technique.

This work aims to evaluate the application of a cylindrical phantom made of dosimetric gel containing alanine pellets distributed inside the gel volume during an end-to-end test of a single isocenter VMAT for simultaneous treatment of multiple brain metastases. The evaluation is based on the comparison of the results obtained with the composite phantom with the treatment planning system (TPS) dose distribution validated by using the clinical conventional quality control with point and planar dose measurements. A cylindrical MAGIC-f gel phantom containing alanine dosimeters (composite phantom) was used to design the VMAT plan in the treatment planning system (TPS). The alanine dosimeters were pellets with radius of 2.5 mm and height of 3 mm, and played the role of brain metastasis inside the gel cylinder, which simulated the cerebral tissue. Five of the alanine dosimeters were selected to simulate five lesions; five planning target volumes (PTVs) were created including the dosimeters and irradiated with different doses. Conventional quality assurance (QA) was performed on the TPS plan and on the composite phantom; a phantom containing only gel (Gel 1 phantom) was also irradiated. One day after irradiation, magnetic resonance images were acquired for both phantoms on a 3T scanner. An electron spin resonance spectrometer was used to evaluate alanine doses. Calibration curves were constructed for the alanine and the gel dosimeters. All the gel only measurement was repeated (Gel 2 phantom) in order to confirm the previous gel measurement. The VMAT treatment plan was approved by the conventional QA. The doses measured by alanine dosimeters on the composite gel phantom agreed to the TPS on average within 3.3%. The alanine dose for each lesion was used to calibrate the gel dosimeter measurements of the concerned PTV. Both gel dose volume histograms (DVH) achieved for each PTV were in agreement with the expected TPS DVH, except for a small discrepancy observed for the Gel 2 curve of PTV1 and the Gel 1 curve of PTV5. In a 3D gamma analyses performed for each PTV volume independently, comparing both the gels' measurements to the TPS and using 3%/3 mm, 5%/2 mm, and 7%/2 mm, more than 90% of the points were approved for all the PTVs, except for the PTV5 comparison in the Gel 1 measurement and for the PTV2 comparison in the Gel 2 measurement. A 3D gamma analysis was also applied for each PTV independently, to compare both gel measurements in order to evaluate the consistence of repeated gel measurements of the same plan, and more than 94.5% of the points were approved. The composite Gel-Alanine phantom can be used for the end-to-end test of a single isocenter VMAT for simultaneous treatment of multiple brain metastases. The use of the alanine as the lesion cores for the treatment planning provided the precise dose measurements inside each lesion and allowed the conversion of the gel R2 values based on an accurate dose measurement inside the target.

Dosimetric evaluation of synthetic CT for magnetic resonance-only based radiotherapy planning of lung cancer

BackgroundInterest in MR-only treatment planning for radiation therapy is growing rapidly with the emergence of integrated MRI/linear accelerator technology. The purpose of this study was to evaluate the feasibility of using synthetic CT images generated from conventional Dixon-based MRI scans for radiation treatment planning of lung cancer.MethodsEleven patients who underwent whole-body PET/MR imaging following a PET/CT exam were randomly selected from an ongoing prospective IRB-approved study. Attenuation maps derived from the Dixon MR Images and atlas-based method was used to create CT data (synCT). Treatment planning for radiation treatment of lung cancer was optimized on the synCT and subsequently copied to the registered CT (planCT) for dose calculation. Planning target volumes (PTVs) with three sizes and four different locations in the lung were planned for irradiation. The dose-volume metrics comparison and 3D gamma analysis were performed to assess agreement between the synCT and CT calculated dose distributions.ResultsMean differences between PTV doses on synCT and CT across all the plans were −0.1% ± 0.4%, 0.1% ± 0.5%, and 0.4% ± 0.5% for D95, D98 and D100, respectively. Difference in dose between the two datasets for organs at risk (OARs) had average differences of −0.14 ± 0.07 Gy, 0.0% ± 0.1%, and −0.1% ± 0.2% for maximum spinal cord, lung V20, and heart V40 respectively. In patient groups based on tumor size and location, no significant differences were observed in the PTV and OARs dose-volume metrics (p > 0.05), except for the maximum spinal-cord dose when the target volumes were located at the lung apex (p = 0.001). Gamma analysis revealed a pass rate of 99.3% ± 1.1% for 2%/2 mm (dose difference/distance to agreement) acceptance criteria in every plan.ConclusionsThe synCT generated from Dixon-based MRI allows for dose calculation of comparable accuracy to the standard CT for lung cancer treatment planning. The dosimetric agreement between synCT and CT calculated doses warrants further development of a MR-only workflow for radiotherapy of lung cancer.

Validation of a method for “dose of the day” calculation in head-neck tomotherapy by using planning ct-to-MVCT deformable image registration

PurposeThe aim of this study was to test the feasibility and dosimetric accuracy of a method that employs planning CT-to-MVCT deformable image registration (DIR) for calculation of the daily dose for head and neck (HN) patients treated with Helical Tomotherapy (HT). MethodsFor each patient, the planning kVCT (CTplan) was deformably registered to the MVCT acquired at the 15th therapy session (MV15) with a B-Spline Free Form algorithm using Mattes mutual information (open-source software 3D Slicer), resulting in a deformed CT (CTdef). On the same day as MVCT15, a kVCT was acquired with the patient in the same treatment position (CT15). The original HT plans were recalculated both on CTdef and CT15, and the corresponding dose distributions were compared; local dose differences <2% of the prescribed dose (DD2%) and 2D/3D gamma-index values (2%-2mm) were assessed respectively with Mapcheck SNC Patient software (Sun Nuclear) and with 3D-Slicer. ResultsOn average, 87.9%±1.2% of voxels were found for DD2% (on average 27 slices available for each patient) and 94.6%±0.8% of points passed the 2D gamma analysis test while the 3D gamma test was satisfied in 94.8%±0.8% of body’s voxels. ConclusionsThis study represents the first demonstration of the dosimetric accuracy of kVCT-to-MVCT DIR for dose of the day computations. The suggested method is sufficiently fast and reliable to be used for daily delivered dose evaluations in clinical strategies for adaptive Tomotherapy of HN cancer.

Multiatlas approach with local registration goodness weighting for MRI-based electron density mapping of head and neck anatomy.

The growing use of magnetic resonance imaging (MRI) as a substitute for computed tomography-based treatment planning requires the development of effective algorithms to generate electron density maps for treatment planning and patient setup verification. The purpose of this work was to develop a method to synthesize computerized tomography (CT) for MR-only radiotherapy of head and neck cancer patients. The algorithm is based on registration of multiple patient datasets containing both MRI and CT images (a "multiatlas" algorithm). Twelve matched pairs of good quality CT and MRI scans (those without apparent motion and blurring artifacts) were selected from a pool of head and neck cancer patients to form the atlas. All atlas MRI scans were preprocessed to reduce scanner- and patient-induced intensity inhomogeneities and to standardize their intensity histograms. Atlas CT and MRIs were coregistered using a novel bone-to-air replacement technique applied to the CT scans that improves the similarity between CTs and MRIs and facilitates the registration process. For each new patient, all atlas MRIs are deformed initially onto the new patients' MRI. We introduce a generalized registration error (GRE) metric that automatically measures the goodness of local registration between MRI pairs. The final synthetic CT value at each point is a nonlinear GRE-weighted average of the atlas CTs. For evaluation, the leave-one-out technique was used for synthetic CT generation and the mean absolute error (MAE) between the original and synthetic CT was computed over the entire CT image. The impact of our proposed CT-MR registration scheme on the accuracy of the final synthetic CT was also studied. The original treatment plans were also recomputed on the new synthetic CTs and dose-volume histogram metrics were compared. In addition, the two-dimensional (2D) gamma analysis at 1%/1mm and 2%/2mm dose difference/distance to agreement was also performed to study the dose distribution at the isocenter. MAE error (±standard deviation) between the original and the synthetic CTs was 64±10, 113±12, and 130±28 Hounsfield Unit (HU) for the entire image, air, and bone regions respectively. Our results showed that our proposed bone-suppression based CT-MR fusion and GRE-weighted strategy could lower the overall MAE error between the original and synthetic CTs by ~69% and ~34% respectively. Dose recalculation comparison showed highly consistent results between plans based on the synthetic vs. the original CTs. The 2D gamma analysis revealed the pass rate of 95.44±2.5 and 99.36±0.71 for 1%/1mm and 2%/2 mm criteria respectively. Due to local registration weighting, the method is robust with respect to MRI imaging artifacts. We developed a novel image analysis technique to synthesize CT for head and neck anatomy. Novel methods were introduced to accurately register atlas CTs and MRIs as well as to weight the final electron density maps using local registration goodness estimates. The resulting accuracy is clinically acceptable, at least for these atlas patients.

Virtual EPID standard phantom audit (VESPA) for remote IMRT and VMAT credentialing

A virtual EPID standard phantom audit (VESPA) has been implemented for remote auditing in support of facility credentialing for clinical trials using IMRT and VMAT. VESPA is based on published methods and a clinically established IMRT QA procedure, here extended to multi-vendor equipment. Facilities are provided with comprehensive instructions and CT datasets to create treatment plans. They deliver the treatment directly to their EPID without any phantom or couch in the beam. In addition, they deliver a set of simple calibration fields per instructions. Collected EPID images are uploaded electronically. In the analysis, the dose is projected back into a virtual cylindrical phantom. 3D gamma analysis is performed. 2D dose planes and linear dose profiles are provided and can be considered when needed for clarification. In addition, using a virtual flat-phantom, 2D field-by-field or arc-by-arc gamma analyses are performed.Pilot facilities covering a range of planning and delivery systems have performed data acquisition and upload successfully.Advantages of VESPA are (1) fast turnaround mainly driven by the facility’s capability of providing the requested EPID images, (2) the possibility for facilities performing the audit in parallel, as there is no need to wait for a phantom, (3) simple and efficient credentialing for international facilities, (4) a large set of data points, and (5) a reduced impact on resources and environment as there is no need to transport heavy phantoms or audit staff. Limitations of the current implementation of VESPA for trials credentialing are that it does not provide absolute dosimetry, therefore a Level I audit is still required, and that it relies on correctly delivered open calibration fields, which are used for system calibration.The implemented EPID based IMRT and VMAT audit system promises to dramatically improve credentialing efficiency for clinical trials and wider applications.

Evaluation of the respiratory motion influence in the 3D dose distribution of IMRT breast radiation therapy treatments

This study aims to evaluate the motion influence in the tridimensional dose distribution due to respiratory for IMRT breast planning technique. To simulate the breathing movement an oscillating platform was used. To simulate the breast, MAGIC-f phantoms were used. CT images of a static phantom were obtained and the IMRT treatment was planned based on them. One phantom was irradiated static in the platform and two other phantoms were irradiated while oscillating in the platform with amplitudes of 0.34 cm and 1.22 cm, the fourth phantom was used as reference in the MRI acquisition. The percentage of points approved in the 3D global gamma analyses (3%/3mm) when comparing the dose distribution of the static phantom with the oscillating ones was 91% for the 0.34cm amplitude and 62% for the 1.22 cm amplitude. Considering this result, the differences found in the dosimetric analyses for the oscillating amplitude of 0.34cm could be considered acceptable in a real treatment. The isodose distribution analyses showed a decrease of dose in the anterior breast region and an increase of dose on the posterior breast region, being these differences most pronounced for large amplitude motion.

Experimental verification of 4D Monte Carlo simulations of dose delivery to a moving anatomy.

To evaluate a novel 4D Monte Carlo simulation tool by comparing calculations to physical measurements using a respiratory motion phantom. We used a dynamic Quasar phantom in both stationary and breathing states (sinusoidal motion of amplitude of 1.8cm and period of 3.3s) for dose measurements on an Elekta Agility linear accelerator. Gafchromic EBT3 film and the RADPOS 4D dosimetry system were placed inside the lung insert of the phantom to measure dose profiles and point-dose values at the center of the spherical tumor inside the insert. Both a static 4×4cm2 field and a VMAT plan were delivered. Static and 4D Monte Carlo simulations of the treatment deliveries were performed using DOSXYZnrc and a modified version of the defDOSXYZnrc user code that allows modeling of the continuous motion of both machine and patient. DICOM treatment plan files and linac delivery log files were used to generate corresponding input files. The phantom motion recorded by RADPOS during beam delivery was incorporated into the input files for the 4DdefDOSXYZnrc simulations. For stationary phantom simulations, all point-dose values from MC simulations at the tumor center agreed within 1% with film and within 2% with RADPOS. More than 98% of the voxels from simulated dose profiles passed a 1D gamma of 2%/2-mm criteria against measured dose profiles. Similar results were observed when applying a 2D gamma analysis with a 2%/2-mm criteria to compare 2D dose distributions of Monte Carlo simulations against measurements. For simulations on the moving phantom, MC-calculated dose values at the center of the tumor were found to be within 1% of film and within 2σ of experimental uncertainties which are 2.8% of the RADPOS measurements. 1D gamma comparisons of the dose profiles were better than 91%, and 2D gamma comparisons of the 2D dose distributions were found to be better than 94%. Our 4D Monte Carlo method using defDOSXYZnrc can be used to accurately calculate the dose distribution in continuously moving anatomy for various treatment techniques. This work, if extended to deformable anatomies, can be used to reconstruct patient delivered dose for use in adaptive radiation therapy.

A method to reconstruct and apply 3D primary fluence for treatment delivery verification.

MotivationIn this study, a method is reported to perform IMRT and VMAT treatment delivery verification using 3D volumetric primary beam fluences reconstructed directly from planned beam parameters and treatment delivery records. The goals of this paper are to demonstrate that 1) 3D beam fluences can be reconstructed efficiently, 2) quality assurance (QA) based on the reconstructed 3D fluences is capable of detecting additional treatment delivery errors, particularly for VMAT plans, beyond those identifiable by other existing treatment delivery verification methods, and 3) QA results based on 3D fluence calculation (3DFC) are correlated with QA results based on physical phantom measurements and radiation dose recalculations.MethodsUsing beam parameters extracted from DICOM plan files and treatment delivery log files, 3D volumetric primary fluences are reconstructed by forward‐projecting the beam apertures, defined by the MLC leaf positions and modulated by beam MU values, at all gantry angles using first‐order ray tracing. Treatment delivery verifications are performed by comparing 3D fluences reconstructed using beam parameters in delivery log files against those reconstructed from treatment plans. Passing rates are then determined using both voxel intensity differences and a 3D gamma analysis. QA sensitivity to various sources of errors is defined as the observed differences in passing rates. Correlations between passing rates obtained from QA derived from both 3D fluence calculations and physical measurements are investigated prospectively using 20 clinical treatment plans with artificially introduced machine delivery errors.ResultsStudies with artificially introduced errors show that common treatment delivery problems including gantry angle errors, MU errors, jaw position errors, collimator rotation errors, and MLC leaf position errors were detectable at less than normal machine tolerances. The reported 3DFC QA method has greater sensitivity than measurement‐based QA methods. Statistical analysis‐based Spearman's correlations shows that the 3DFC QA passing rates are significantly correlated with passing rates of physical phantom measurement‐based QA methods.ConclusionAmong measurement‐less treatment delivery verification methods, the reported 3DFC method is less demanding than those based on full dose re‐calculations, and more comprehensive than those that solely checks beam parameters in treatment log files. With QA passing rates correlating to measurement‐based passing rates, the 3DFC QA results could be useful for complementing the physical phantom measurements, or verifying treatment deliveries when physical measurements are not available. For the past 4+ years, the reported method has been implemented at authors’ institution 1) as a complementary metric to physical phantom measurements for pretreatment, patient‐specific QA of IMRT and VMAT plans, and 2) as an important part of the log file‐based automated verification of daily patient treatment deliveries. It has been demonstrated to be useful in catching both treatment plan data transfer errors and treatment delivery problems.